vs
Electromed, Inc.（ELMD）与TransMedics Group, Inc.（TMDX）财务数据对比。点击上方公司名可切换其他公司
TransMedics Group, Inc.的季度营收约是Electromed, Inc.的8.5倍（$160.8M vs $18.9M）。TransMedics Group, Inc.净利率更高（65.6% vs 14.6%，领先50.9%）。TransMedics Group, Inc.同比增速更快（32.2% vs 16.3%）。TransMedics Group, Inc.自由现金流更多（$19.0M vs $2.4M）。过去两年TransMedics Group, Inc.的营收复合增速更高（28.8% vs 16.7%）
Electromed, Inc.是一家专注于呼吸护理设备研发、生产与销售的医疗设备企业，核心产品为高频胸壁振荡排痰系统，主要服务美国市场的家庭护理及临床医疗机构，为囊性纤维化、慢阻肺等呼吸系统疾病患者提供气道清理解决方案。
TransMedics Group, Inc.是一家专注于器官移植领域的医疗科技企业，核心产品器官护理系统可在运输过程中维持捐献器官的活性，提升心、肺、肝、肾移植手术的成功率，服务覆盖北美、欧洲及亚太地区的移植中心与器官获取组织。
ELMD vs TMDX — 直观对比
营收规模更大
TMDX
是对方的8.5倍
$18.9M
营收增速更快
TMDX
高出15.9%
16.3%
净利率更高
TMDX
高出50.9%
14.6%
自由现金流更多
TMDX
多$16.6M
$2.4M
两年增速更快
TMDX
近两年复合增速
16.7%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $18.9M | $160.8M |
| 净利润 | $2.8M | $105.4M |
| 毛利率 | 78.4% | 58.1% |
| 营业利润率 | 19.2% | 13.2% |
| 净利率 | 14.6% | 65.6% |
| 营收同比 | 16.3% | 32.2% |
| 净利润同比 | 40.3% | 1436.9% |
| 每股收益（稀释后） | $0.32 | $2.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ELMDTMDX
| Q4 25 | $18.9M | $160.8M | ||
| Q3 25 | $16.9M | $143.8M | ||
| Q2 25 | $17.4M | $157.4M | ||
| Q1 25 | $15.7M | $143.5M | ||
| Q4 24 | $16.3M | $121.6M | ||
| Q3 24 | $14.7M | $108.8M | ||
| Q2 24 | $14.8M | $114.3M | ||
| Q1 24 | $13.9M | $96.8M |
净利润ELMDTMDX
| Q4 25 | $2.8M | $105.4M | ||
| Q3 25 | $2.1M | $24.3M | ||
| Q2 25 | $2.2M | $34.9M | ||
| Q1 25 | $1.9M | $25.7M | ||
| Q4 24 | $2.0M | $6.9M | ||
| Q3 24 | $1.5M | $4.2M | ||
| Q2 24 | $1.8M | $12.2M | ||
| Q1 24 | $1.5M | $12.2M |
毛利率ELMDTMDX
| Q4 25 | 78.4% | 58.1% | ||
| Q3 25 | 78.1% | 58.8% | ||
| Q2 25 | 78.3% | 61.4% | ||
| Q1 25 | 78.0% | 61.5% | ||
| Q4 24 | 77.7% | 59.2% | ||
| Q3 24 | 78.3% | 55.9% | ||
| Q2 24 | 76.2% | 60.6% | ||
| Q1 24 | 74.8% | 61.9% |
营业利润率ELMDTMDX
| Q4 25 | 19.2% | 13.2% | ||
| Q3 25 | 15.8% | 16.2% | ||
| Q2 25 | 17.5% | 23.2% | ||
| Q1 25 | 13.6% | 19.1% | ||
| Q4 24 | 15.6% | 7.1% | ||
| Q3 24 | 13.2% | 3.6% | ||
| Q2 24 | 15.7% | 10.9% | ||
| Q1 24 | 13.3% | 12.8% |
净利率ELMDTMDX
| Q4 25 | 14.6% | 65.6% | ||
| Q3 25 | 12.6% | 16.9% | ||
| Q2 25 | 12.7% | 22.2% | ||
| Q1 25 | 12.1% | 17.9% | ||
| Q4 24 | 12.1% | 5.6% | ||
| Q3 24 | 10.0% | 3.9% | ||
| Q2 24 | 12.3% | 10.7% | ||
| Q1 24 | 10.8% | 12.6% |
每股收益（稀释后）ELMDTMDX
| Q4 25 | $0.32 | $2.59 | ||
| Q3 25 | $0.25 | $0.66 | ||
| Q2 25 | $0.26 | $0.92 | ||
| Q1 25 | $0.21 | $0.70 | ||
| Q4 24 | $0.22 | $0.19 | ||
| Q3 24 | $0.16 | $0.12 | ||
| Q2 24 | $0.20 | $0.35 | ||
| Q1 24 | $0.17 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $13.8M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $45.4M | $473.1M |
| 总资产 | $54.9M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ELMDTMDX
| Q4 25 | $13.8M | — | ||
| Q3 25 | $14.1M | — | ||
| Q2 25 | $15.3M | — | ||
| Q1 25 | $15.2M | — | ||
| Q4 24 | $16.2M | — | ||
| Q3 24 | $13.9M | $330.1M | ||
| Q2 24 | $16.1M | $362.8M | ||
| Q1 24 | $11.7M | $350.2M |
股东权益ELMDTMDX
| Q4 25 | $45.4M | $473.1M | ||
| Q3 25 | $44.7M | $355.2M | ||
| Q2 25 | $43.2M | $318.1M | ||
| Q1 25 | $43.9M | $266.3M | ||
| Q4 24 | $43.6M | $228.6M | ||
| Q3 24 | $41.5M | $209.9M | ||
| Q2 24 | $44.5M | $189.9M | ||
| Q1 24 | $42.5M | $159.5M |
总资产ELMDTMDX
| Q4 25 | $54.9M | $1.1B | ||
| Q3 25 | $53.6M | $946.0M | ||
| Q2 25 | $53.8M | $890.5M | ||
| Q1 25 | $52.5M | $837.5M | ||
| Q4 24 | $52.3M | $804.1M | ||
| Q3 24 | $48.9M | $785.6M | ||
| Q2 24 | $52.2M | $758.6M | ||
| Q1 24 | $48.9M | $723.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.0M | $34.5M |
| 自由现金流经营现金流 - 资本支出 | $2.4M | $19.0M |
| 自由现金流率自由现金流/营收 | 12.7% | 11.8% |
| 资本支出强度资本支出/营收 | 3.4% | 9.7% |
| 现金转化率经营现金流/净利润 | 1.10× | 0.33× |
| 过去12个月自由现金流最近4个季度 | $7.9M | $133.6M |
8季度趋势，按日历期对齐
经营现金流ELMDTMDX
| Q4 25 | $3.0M | $34.5M | ||
| Q3 25 | $169.0K | $69.6M | ||
| Q2 25 | $3.9M | $91.6M | ||
| Q1 25 | $2.1M | $-2.9M | ||
| Q4 24 | $3.2M | $19.7M | ||
| Q3 24 | $2.3M | $6.9M | ||
| Q2 24 | $4.5M | $25.7M | ||
| Q1 24 | $1.4M | $-3.4M |
自由现金流ELMDTMDX
| Q4 25 | $2.4M | $19.0M | ||
| Q3 25 | $-83.0K | $61.9M | ||
| Q2 25 | $3.7M | $82.5M | ||
| Q1 25 | $1.9M | $-29.9M | ||
| Q4 24 | $2.9M | $6.1M | ||
| Q3 24 | $2.3M | $-41.3M | ||
| Q2 24 | $4.5M | $2.0M | ||
| Q1 24 | $1.3M | $-47.6M |
自由现金流率ELMDTMDX
| Q4 25 | 12.7% | 11.8% | ||
| Q3 25 | -0.5% | 43.1% | ||
| Q2 25 | 21.4% | 52.4% | ||
| Q1 25 | 12.2% | -20.8% | ||
| Q4 24 | 18.0% | 5.0% | ||
| Q3 24 | 15.5% | -38.0% | ||
| Q2 24 | 30.1% | 1.7% | ||
| Q1 24 | 9.1% | -49.2% |
资本支出强度ELMDTMDX
| Q4 25 | 3.4% | 9.7% | ||
| Q3 25 | 1.5% | 5.3% | ||
| Q2 25 | 0.8% | 5.8% | ||
| Q1 25 | 1.0% | 18.8% | ||
| Q4 24 | 1.4% | 11.2% | ||
| Q3 24 | 0.3% | 44.3% | ||
| Q2 24 | 0.1% | 20.8% | ||
| Q1 24 | 0.6% | 45.6% |
现金转化率ELMDTMDX
| Q4 25 | 1.10× | 0.33× | ||
| Q3 25 | 0.08× | 2.86× | ||
| Q2 25 | 1.75× | 2.62× | ||
| Q1 25 | 1.10× | -0.11× | ||
| Q4 24 | 1.60× | 2.87× | ||
| Q3 24 | 1.57× | 1.63× | ||
| Q2 24 | 2.46× | 2.11× | ||
| Q1 24 | 0.90× | -0.28× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ELMD
暂无分部数据
TMDX
| Liver Product | $127.0M | 79% |
| Heart Product | $26.0M | 16% |
| Other | $5.9M | 4% |
| Lung Product | $1.9M | 1% |
